MMR and BCR::ABL1^IS ≤1% at week 156. MMR (BCR::ABL1^IS ≤0.1%). ∗Based on the full analysis set. In patients without MMR at week 156, the reasons were treatment failure (asciminib, n = 3; bosutinib, n = 5), missing assessments (asciminib, n = 3), and lost response (asciminib, n = 1). †The treatment difference, after adjusting for the baseline MCyR status, was 23.16% (95% CI, 13.14-33.18; 2-sided P < .001) at week 156. ‡Based on 142 of 157 patients (90.4%) who received asciminib and 72 of 76 (94.7%) who received bosutinib with BCR::ABL1^IS >1% at baseline. §The treatment difference after adjusting for MCyR status at baseline was 32.34% (95% CI, 21.44-43.24; 2-sided P < .001) at week 156.